2023年4月13日

洛杉磯,加利福尼亞,2023年3月31日洛杉磯,加利福尼亞,3月31日2023 -能力的生物,Inc . mitochondria-focused生物科技公司發展小說mitophagy調節器,今天宣布的3500萬美元的融資。領先的生命科學投資者RA資本管理和洞察力的合作夥伴共同融資和加入現有投資者飛羽企業支持能力的加速生物first-in-class mitophagy興奮劑,預計在2024年進入臨床試驗。融資也將推動能力的臨床項目集中在新的線粒體調節器。私人,洛杉磯生物科技公司開發一種創新的mitophagy治療平台,能力生物發現了一個新奇的細胞誘導線粒體營業額目標,導致線粒體質量和性能的改善。能力在神經退行性的管道包括機會和自身免疫性疾病、肌肉疾病和遺傳孤兒的跡象。能力生物被飛羽種子企業的創始人和合夥人芋頭稻葉型。作為融資的一部分,克裏斯蒂娜Ghenoiu博士,RA資本管理負責人和迪倫莫裏斯,董事總經理了解合作夥伴加入董事會。“這融資能力的生物是一個重要的裏程碑,我們興奮的支持與合作等經驗豐富的投資者,“肯·霍恩表示,首席執行官生物的能力。“這進展我們會mitophagy受體激動劑進入診所,以及擴大我們的線粒體調節器”的管道。“Mitophagy is a fundamental biological process, and disruptions can drive pathology in numerous tissues. Thus, we are excited to collaborate with world-leading mitochondrial scientists and researchers to advance the platform and enable the clinical development of Capacity Bio’s novel small molecule drugs,” commented Dr. Ghenoiu. Dylan Morris added: “Capacity Bio’s mitochondrial characterization platform has produced highly compelling assets for multiple diseases, and we are excited to support their growth into a clinical stage company. We believe Capacity’s programs are ideally suited to address multiple devastating diseases with huge unmet clinical need.” “I am excited that Capacity is moving forward cutting-edge mitochondrial biology,” said Orian Shirihai, MD, PhD, co-founder and professor at University of California Los Angeles. “It is the product of 15 years of research by the scientific community into the mechanisms that allow our cells to maintain their functions under stress.” About Capacity Bio Capacity Bio is a private, Los Angeles-based biotech company developing a first-in-class mitophagy therapeutic platform, along with the most advanced analytical toolkit to characterize mitochondria. The team has discovered a novel cellular target that induces mitochondrial turnover, resulting in improved mitochondrial quality. Capacity’s pipeline includes opportunities in neurodegenerative and autoimmune disorders, myopathies, and genetic orphan indications. Media Contact